Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 18/20 | 0.57 |
| ▸ | MAOA | P21397 | 10/20 | 0.56 |
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108844 | 0.92 | ALDH2 (0.54) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2107963 | 0.92 | ALDH2 (0.67) | ALDH2MAOAMAOB | |
| SCHEMBL3421810 | 0.92 | MAPT (0.61) | ALDH2MAOAMAOBMRGPRX4ALDH1A1 | |
| SCHEMBL2107835 | 0.91 | ALDH2 (0.56) | ALDH2MAOAMAOBMRGPRX4ALDH1A1 | |
| SCHEMBL21635206 | 0.91 | ALDH2 (0.56) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2106313 | 0.90 | MAPT (0.55) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2108139 | 0.87 | ALDH2 (0.51) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2108852 | 0.87 | ALDH2 (0.53) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2107964 | 0.87 | ALDH2 (0.53) | ALDH2MAOAMAOBMRGPRX4ALDH1A1 | |
| SCHEMBL2108855 | 0.87 | ALDH2 (0.53) | ALDH2MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863424-A1 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | Amygdala Neurosciences, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3697415-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | Amygdala Neurosciences, Inc. (US) | 2020-08-26 | — | — | EP | claimed |
| WO-2019079209-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2019-04-25 | — | — | WO | claimed |
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | claimed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | claimed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-3863424-A1 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | Amygdala Neurosciences, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210220376-A1 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | AMYGDALA NEUROSCIENCES, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| EP-3829562-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | Amygdala Neurosciences, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210145844-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200237789-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | disclosed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAOA 62/4885MAOB 47/4885 |
| US-20210145844-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | CHRNA2, ALDH2, ALDH1A1 | ALDH2 2/4885MAOA 92/4885MAOB 86/4885 |
| US-20200237789-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | ALDH2, ALDH1A1, ALDH3A1 | ALDH2 1/4885MAOA 48/4885MAOB 40/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAOA 62/4885MAOB 47/4885 |
| US-20210220376-A1 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | ADH1A, ADH1C, ALDH1A1 | ALDH2 6/4885MAOA 35/4885MAOB 33/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 4/4885MAOA 62/4885MAOB 45/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | ALDH2 1/4885MAOA 59/4885MAOB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.